drugset / Trial / NCT05965856
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.
Timeline
- Start
- 2023-12-11
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izalontamab Brengitecan | Unknown | — | Intravenous |
| Subject | SI-B003 | Monoclonal antibody | — | Intravenous |